Esperion Therapeutics Long Term Debt

Esperion Therapeutics (ESPR) currently reports a long-term debt of $250M as of March 2026. That compares with $240M in the prior-year period — up 4.4% year over year. Use the charts on this page to explore Esperion Therapeutics's long-term debt history and peer comparisons.

Esperion Therapeutics's long-term debt increased from $240M to $250M — a 4.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Esperion Therapeutics reported $250M in long-term debt as of March 2026. That compares with $240M in the prior-year period — up 4.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $250M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Esperion Therapeutics, and consider following ESPR for alerts when major investors trade the stock.

Esperion Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $250M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ESPR with unrelated industries.